Searched for
MACQUARIE ON CDMO FIRMS
India becoming an attractive option for global pharmaceutical supply chain: Macquarie ReportIndia's CRDMO industry is projected to grow from USD 7 billion to USD 14 billion by 2028, driven by pharmaceutical outsourcing and regulato...- Macquarie initiates coverage on Divi’s Labs, 3 CRDMO firms with up to 40% upside potentialThe global brokerage firm highlights that Indian CDMO companies trade at a 2-year forward EV/EBITDA of 20x, compared to 16x for regional an...
- Hot Stocks: Brokerage views on Mphasis, Ashok Leyland, ITC and Piramal PharmaMacquarie has downgraded Mphasis to underperform and lowered its target price, while maintaining an outperform rating on Mastek. Bofa Secur...
- Load More